SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 3 — Focused Visit (Follow-up) — Gwen Ifill — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientGwen Ifill
Date of birth1955-09-29
IdentifiersMRN HR-ML032-SYN-TD; SSN (made up) 000-32-5814
Document date2016-02-24
AuthorLorna Achebe-Price, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Review three weeks after surgical staging, on the first treatment day. [S]

History of Present Illness

Ms. Ifill returns three weeks after robotic-assisted hysterectomy with removal of both tubes and ovaries, sentinel node mapping and removal of the enlarged para-aortic node. She went home the next morning, needed acetaminophen for about a week and nothing since, and has had no bleeding, fever, leg swelling or bladder trouble. She went back to work last week. The final pathology and molecular results are back, and the multidisciplinary tumor board reviewed them with Dr. Delacroix. She saw the genetic counselor this morning. She came today for her first cycle of dostarlimab with carboplatin and paclitaxel. She has had no thoughts of self-harm. [S]

ElementDetail
OperationMinimally invasive; home the next day; port sites healed
PathologyEndometrioid adenocarcinoma, grade 2, 65% myometrial invasion; right pelvic sentinel node and one para-aortic node involved
Stage and molecular classFIGO 2013 stage IIIC2ii; POLE wild-type, MMRd, p53 wild-type
Lynch syndrome screenMLH1 promoter hypermethylated: acquired, not inherited
TodayCycle 1 of dostarlimab, carboplatin and paclitaxel

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever; weight 72.6 kg
GenitourinaryNegativeNo vaginal bleeding or discharge; no urinary symptoms
GastrointestinalNegativeNo nausea, diarrhea or abdominal pain
NeurologicalNegativeNo tingling or numbness in the hands or feet
CardiovascularNegativeNo calf pain or leg swelling
IntegumentaryNegativeNo rash
PsychiatricNegativeMood steady; PHQ-9 5; no thoughts of self-harm

7 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for pain after surgery, no more than 3 g a dayTwo tablets every 6 hours as neededOral route2016-02-03 to 2016-02-17completedS
Dostarlimab 50 mg/mL injection, 500 mg intravenously over 30 minutes on day 1 of each 21-day cycle, before carboplatin and paclitaxel, for six cyclesDay 1 every 21 days for six cyclesIntravenous route2016-02-24 to 2016-06-09completedS
Carboplatin 10 mg/mL injection, 575 mg (AUC 5) intravenously on day 1 of each 21-day cycle, for six cyclesDay 1 every 21 days for six cyclesIntravenous route2016-02-24 to 2016-06-09completedS
Paclitaxel 6 mg/mL injection, 320 mg (175 mg/m2) intravenously over 3 hours on day 1 of each 21-day cycle, for six cycles, after dexamethasone, diphenhydramine and famotidineDay 1 every 21 days for six cyclesIntravenous route2016-02-24 to 2016-06-09completedS
Ondansetron 8 mg oral tablet, one tablet by mouth every 8 hours as needed for nauseaOne tablet every 8 hours as needed for nauseaOral route2016-02-24 to 2016-06-30completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2016-02-24Body height165cmS
2016-02-24Body weight72.6kgS
2016-02-24Body mass index (BMI) [Ratio]26.7kg/m2S
2016-02-24Systolic blood pressure124mm[Hg]S
2016-02-24Diastolic blood pressure78mm[Hg]S
2016-02-24Heart rate80/minS
2016-02-24Respiratory rate16/minS
2016-02-24Body temperature36.7CelS
2016-02-24Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2016-02-24Hemoglobin [Mass/volume] in Blood11.6g/dL12-15.5 g/dLLowS
2016-02-24Leukocytes [#/volume] in Blood by Automated count6.410*3/uL4-11 10*3/uLNormalS
2016-02-24Neutrophils [#/volume] in Blood by Automated count3.910*3/uL1.5-7.7 10*3/uLNormalS
2016-02-24Platelets [#/volume] in Blood by Automated count30110*3/uL150-400 10*3/uLNormalS
2016-02-24Creatinine [Mass/volume] in Serum or Plasma0.78mg/dL0.59-1.04 mg/dLNormalS
2016-02-24Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2011)/1.73 sq M87mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
2016-02-24Glucose [Mass/volume] in Serum or Plasma92mg/dL70-99 mg/dLNormalS
2016-02-24Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma18U/L7-35 U/LNormalS
2016-02-24Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma20U/L8-35 U/LNormalS
2016-02-24Bilirubin.total [Mass/volume] in Serum or Plasma0.4mg/dL0.1-1.2 mg/dLNormalS
2016-02-24Albumin [Mass/volume] in Serum or Plasma4g/dL3.5-5 g/dLNormalS
2016-02-24Magnesium [Mass/volume] in Serum or Plasma2mg/dL1.7-2.2 mg/dLNormalS
2016-02-24Thyrotropin [Units/volume] in Serum or Plasma1.9m[IU]/L0.4-4.5 mIU/LNormalS
2016-02-24Thyroxine (T4) free [Mass/volume] in Serum or Plasma1.2ng/dL0.8-1.8 ng/dLNormalS
2016-02-24Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S

Physical Exam

Vital signs recorded on 2016-02-24; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 124/78, pulse 80; weight 72.6 kg
AbdomenPort-site incisions healed without redness or hernia; soft, non-tender
ExtremitiesNo leg or genital swelling; calf circumferences equal (baseline for lymphedema)
NeurologicalLight touch, pinprick and vibration normal in the hands and feet; ankle reflexes present (baseline before paclitaxel)
SkinNo rash (baseline before a checkpoint inhibitor)
PsychiatricFocused and well informed; asks detailed questions

Problems

ProblemClinical statusVerificationCodeProvenance
Postmenopausal bleeding for three weeks, about eight years after her last period, in a woman of 60 who takes no hormone therapy: endometrial cancer must be excluded. Office endometrial biopsy taken today, transvaginal ultrasound this week, and gynecologic oncology review bookedresolvedconfirmed N95.0S — Synthetic presenting problem; no symptom of her real illness was made public. Superseded by the diagnosis at the gynecologic oncology consultation.
Endometrioid adenocarcinoma of the endometrium, FIGO grade 2, mismatch repair deficient (loss of MLH1 and PMS2 staining), p53 wild-type pattern, on office endometrial biopsy, with enlarged right pelvic and para-aortic lymph nodes on CT; surgical staging planned; synthetic modern detail linked to her publicly reported endometrial canceractiveconfirmed C54.1S — Synthetic histology, molecular result and extent; her family gave endometrial cancer as the cause of death (D), and nothing more about it was made public.
Metastatic endometrioid carcinoma in the right external iliac sentinel lymph node (9 mm deposit) and a left para-aortic lymph node (14 mm deposit), with the other nodes removed negative: FIGO 2013 stage IIIC2iiactiveconfirmed C77.8S — Synthetic nodal disease found at surgical staging.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratorySurgical pathology, stage and molecular classAfter surgeryUp to dateFIGO 2013 stage IIIC2ii; POLE wild-type, MMRd, p53 wild-type; estrogen receptor positive
LaboratoryMLH1 promoter methylationReflex when MLH1 is lostUp to dateHypermethylated: the mismatch repair loss is acquired in the tumor
ReferralGenetic counselingWhen the tumor screen is abnormalCompleted todaySeen this morning; the result was explained
LaboratoryGermline testing for Lynch syndrome and cascade testing of relativesIf MMR loss is not explained by MLH1 methylation, or with a strong family historyNot indicatedMLH1 loss is explained by promoter methylation; she knows that a new family history of colorectal or endometrial cancer at a young age would be a reason to revisit this
LaboratoryHepatitis B, hepatitis C and HIV screeningBefore systemic cancer treatmentUp to dateAll negative; no antiviral prophylaxis needed
LaboratoryBlood count with neutrophils and plateletsBefore each chemotherapy cycleCompleted todayHemoglobin 11.6 g/dL, white cells 6.4, neutrophils 3.9, platelets 301
LaboratoryCreatinine and estimated kidney function (carboplatin dose)Before each cycleCompleted todayCreatinine 0.78 mg/dL, eGFR 87; carboplatin 575 mg for AUC 5
LaboratoryLiver tests (paclitaxel and checkpoint inhibitor)Baseline and before each checkpoint inhibitor doseCompleted todayALT 18, AST 20 U/L, bilirubin 0.4 mg/dL, albumin 4.0 g/dL
LaboratoryMagnesiumBefore each cycleCompleted today2.0 mg/dL
LaboratoryTSH and free T4 (immune-related thyroid disease)Baseline and before each checkpoint inhibitor doseCompleted todayTSH 1.9 mIU/L, free T4 1.2 ng/dL (baseline)
LaboratoryGlucose (immune-related diabetes)Baseline and before each checkpoint inhibitor doseCompleted today92 mg/dL (baseline)
LaboratoryMorning cortisol (immune-related adrenal and pituitary disease)Baseline and before each checkpoint inhibitor doseDeferredNot drawn: she arrived after the morning window, when a cortisol cannot be read. To be drawn before 9 a.m. before cycle 2 in the infusion center. No symptom of adrenal insufficiency
ExaminationPeripheral neuropathy: symptoms and examinationBaseline and before each taxane cycleCompleted todayBaseline normal before the first paclitaxel dose
ExaminationLymphedemaEach visit after lymph node surgeryCompleted todayNo swelling; baseline calf measurements recorded
Medication safetyNausea and vomiting controlEach cycleCompleted todayThree-drug preventive regimen for carboplatin (an NK1 antagonist, a 5-HT3 antagonist and dexamethasone); ondansetron at home
Medication safetyPaclitaxel infusion reaction preventionEach paclitaxel doseCompleted todayDexamethasone, diphenhydramine and famotidine before the infusion; observation in the first hour
Medication safetyImmune-related adverse event teachingBefore the first checkpoint inhibitor dose and each visitCompleted todayWallet card and written list of symptoms to report the same day
SurveyDistress and depression screen (PHQ-9)At diagnosis, each treatment phase, and when symptoms changeCompleted todayPHQ-9 5; no thoughts of self-harm

Goal progress:

Guideline basis: NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms (2026); Berek JS, et al. FIGO staging of endometrial cancer: 2023. Int J Gynaecol Obstet 2023;162(2):383-394 (PMID 37337978) (2023); Mirza MR, et al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer (RUBY). N Engl J Med 2023;388(23):2145-2158 (PMID 36972026) (2023); Eskander RN, et al. Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer (NRG-GY018). N Engl J Med 2023;388(23):2159-2170 (PMID 36972022) (2023); JEMPERLI (dostarlimab-gxly) injection, prescribing information (2026); Salani R, et al. Updates to post-treatment surveillance after curative intent treatment for patients with gynecologic cancers: A Society of Gynecologic Oncology clinical practice statement. Gynecol Oncol 2026;204:109-117 (PMID 41308226) (2026); ACOG Practice Bulletin No. 147: Lynch syndrome. Obstet Gynecol 2014;124(5):1042-1054 (PMID 25437740) (2014); Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. J Clin Oncol 2021;39(36):4073-4126 (PMID 34724392) (2021); Hesketh PJ, et al. Antiemetics: ASCO Guideline Update. J Clin Oncol 2020;38(24):2782-2797 (2020); Loprinzi CL, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol 2020;38(28):3325-3348 (2020); Hwang JP, et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. J Clin Oncol 2020 (2020); CMID: Clinical Monitoring Intelligence Database, endometrial cancer and hypothyroidism monographs (2026); Depression and Suicide Risk in Adults: Screening (2023)

Follow-up: Cycles every 21 days in the infusion center, with blood counts, chemistry, TSH and a morning cortisol before cycle 2. Primary care and gynecologic oncology review at cycle 4. Call at once for a temperature of 38.0 °C or more, diarrhea, rash, cough or breathlessness. Next scheduled visit 2016-04-28: midpoint of combination treatment: blood counts, immune-related adverse event checks, neuropathy, and mood. [S]